Oraqix
Oraqix is a revolutionary new non-injection anesthetic for periodontal applications. The anesthetic is delivered to the treatment site without the use of a needle and anesthetizes the site within 30 seconds for a period of approximately 20 minutes, without residual numbness of lips and tongue.
Patient Advantage Summary:
No Needle
Quick Acting Anesthetic
No Residual Numbness (you can eat after treatment!)
-
Q: What is Oraqix used for?
A: Oraqix is indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing procedures. -
Q: How does Oraqix work?
A: The active ingredients lidocaine base and prilocaine base in Oraqix anesthesia the nerves in the gingival margin and periodontal pockets where it is applied without the use of shots. -
Q: How long do I have wait before the anesthetize takes effect?
A: Treatment can begin 60seconds after application. -
Q: Will Oraqix numb the surrounding tissues?
A: No, this is one of the benefits of Oraqix, it will not cause numbness to the surrounding tissues, including lips and tongue. -
Q: How quickly will the effects of Oraqix wear off?
A: The duration of anesthesia is about 20 minutes (individual overall range 14-31 minutes), though this can differ between patients. -
Q: Is Oraqix contraindicated for any patient groups?
A: Prilocaine can cause elevated methemoglobin levels particularly in conjunction with methemoglobin-inducing agents. Methemoglobinemia has also been reported in a few cases in association with lidocaine treatment.
Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic Methemoglobinemia are more susceptible to drug-induced Methemoglobinemia: Oraqix should not be used in those patients with congenital or idiopathic Methemoglobinemia and in infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents.
Patients taking drugs associated with drug-induced Methemoglobinemia such as sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbitol, phenytoin, primaquine, and quinine are at greater risk for developing Methemoglobinemia. -
Q: What are the side effects of Oraqix?
A: The most common adverse reactions in clinical studies were application site reactions, headaches, and taste alteration.